RCUS supply chain intelligence for Arcus Biosciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Arcus Biosciences, Inc. (RCUS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TAIHO | TAIHO | 90% | The Company has full rights to casdatifan and the casdatifan development program, other than those rights licensed to Taiho in Japan and certain other Asian territories (not including China) |
| WUXI-BIOLOGICS | WUXI-BIOLOGICS | 90% | For example, WuXi Biologics, located in China, is currently our sole manufacturer of zimberelimab and domvanalimab. |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from AZN grap… |
| CLDX | Celldex Therapeutics, Inc. | 72% | ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| CLDX | Celldex Therapeutics, Inc. | 72% | Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers … |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: 48 434 238 116 47 401 8 % Total HIV 15,918 2,339 1,355 19,612 14,848 2,102 1,226 18,175 8 % Liver Disease Sofosbuvir/Velpatasvir (3) 922 299 374 1,596 859 323… |
| HTGC | Hercules Capital, Inc. | 72% | Reciprocal relationship from HTGC graph: Reciprocal relationship from RCUS graph: Item 1A. Risk Factors. You should consider carefully the following risk factors, together with all the other informat… |
| IPHA | Innate Pharma S.A. | 72% | Reciprocal relationship from IPHA graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers … |
| IPHA | Innate Pharma S.A. | 72% | ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from MRK grap… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers… |
| SNYNF | Sanofi | 72% | ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GILEAD | GILEAD | 92% | Revenues from Gilead accounted for 88 % and 100 % of Total revenues for the three months ended March 31, 2026 and 2025, respectively. |
| TAIHO | TAIHO | 90% | License and development services revenue consists of amounts recognized from the portions of the nonrefundable upfront payments received from Gilead and Taiho |
| AZN | AstraZeneca PLC | 72% | nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along with Gilead’s internal manufacturing infra… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from RCUS graph: nd clinical testing. If any of our op… |
| CLDX | Celldex Therapeutics, Inc. | 72% | Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: ny of our investigational products … |
| CLDX | Celldex Therapeutics, Inc. | 72% | ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from RCUS graph: hase Agreement Amendment; and $ million deferred revenue remaining from the First Gilead Collaboration Agreement Amen… |
| GILD | Gilead Sciences, Inc. | 72% | hase Agreement Amendment; and $ million deferred revenue remaining from the First Gilead Collaboration Agreement Amendment effective December 2021. We determined the entire $ million to be the alloca… |
| HTGC | Hercules Capital, Inc. | 72% | non-public information and for complying with our disclosure obligations under the Regulation FD. Such disclosures will be included on the company’s website under the heading "Investors & Media." Acc… |
| HTGC | Hercules Capital, Inc. | 72% | Reciprocal relationship from HTGC graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from HTGC g… |
| IPHA | Innate Pharma S.A. | 72% | ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| IPHA | Innate Pharma S.A. | 72% | Reciprocal relationship from IPHA graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers … |
| MRK | Merck & Co., Inc. | 72% | nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along with Gilead’s internal manufacturing infra… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from MRK grap… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from REGN g… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| SNYNF | Sanofi | 72% | ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from SNYN… |
| BEIGENE-LTD | BEIGENE-LTD | 62% | nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along with Gilead’s internal manufacturing infra… |
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | ith Hercules at the end of the second quarter 2025. Income Tax Expense There was no Income tax expense for the three months ended March 31, 2026 or 2025 due to forecasted full year NOLs. Liquidity an… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| RCUS-DEBT | Debt stack $101.0M | 90% | Market cache reports total debt of $101.0M. |
| RCUS-DEBT-12082 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2018-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| RCUS-OWNER-GILEAD-SCIENCES-INC | GILEAD SCIENCES, INC. | 90% | 13F overlay lists GILEAD SCIENCES, INC. as top holder; 213 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer', 'supplier'] |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CLDX | Celldex Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |